Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2003 Sep 8;3(1):18.
doi: 10.1186/1472-6963-3-18.

The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis

Atle Fretheim  1 , Morten Aaserud, Andrew D Oxman
Affiliations
Comparative Study

The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis

Atle Fretheim et al. BMC Health Serv Res. .

Abstract

Background: All clinical practice guidelines recommend thiazides as a first-choice drug for the management of uncomplicated hypertension. Thiazides are also the lowest priced antihypertensive drugs. Despite this, the use of thiazides is much lower than that of other drug-classes. We wanted to estimate the potential for savings if thiazides were used as the first choice drug for the management of uncomplicated hypertension.

Methods: For six countries (Canada, France, Germany, Norway, the UK and the US) we estimated the number of people that are being treated for hypertension, and the proportion of them that are suitable candidates for thiazide-therapy. By comparing this estimate with thiazide prescribing, we calculated the number of people that could switch from more expensive medication to thiazides. This enabled us to estimate the potential drug-cost savings. The analysis was based on findings from epidemiological studies and drug trials, and data on sales and prescribing provided by IMS for the year 2000.

Results: For Canada, France, Germany, Norway, the UK and the US the estimated potential annual savings were US13.8 million dollars, US37.4 million dollars, US72.2 million dollars, US10.7 million dollars, US119.7 million dollars and US433.6 million dollars, respectively.

PubMed Disclaimer

References

    1. Wright JM, Lee C, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a firstline drug? Can Med Assoc J. 1999;161:25–32. - PMC - PubMed
    1. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood- pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955–1964. doi: 10.1016/S0140-6736(00)03307-9. - DOI - PubMed
    1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–2997. doi: 10.1001/jama.288.23.2981. - DOI - PubMed
    1. Wright JM. Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 1: Thiazide diuretics. Can Med Assoc J. 2000;163:57–60. - PMC - PubMed
    1. Fretheim A, Williams Jr. JW, Oxman AD, Herrin J. The relation between methods and recommendations in clinical practice guidelines for hypertension and hyperlipidemia. J Fam Pract. 2002;51:963–968. - PubMed

Publication types

MeSH terms